Market report: ResMed announces record quarterly results
Friday, 28 January, 2011
ResMed (ASX:RMD), maker of sleep and respiratory medical devices, announced today record revenue and income for the last quarter of 2010, although investors in the ASX took 2.5% off the company's stock price in morning trading.
The company posted a revenue for the quarter ending December 31, 2010, of US$306 million, which is up 11% on the same quarter for 2009, largely on the back of sales of its S9 AutoSet sleep therapy system.
The lion's share of the growth occurred in the European and Asia-Pacific regions, which saw a 12% year-on-year growth, or 17% at a constant currency basis. Growth in the United States was lower, at 10%.
Expenses also increased over the quarter, primarily due to increased demand for sales support.
Research and development expenses were US$22 million, or 7% of revenue, an increase of 15% (or 10% at constant currency) year-on-year.
Even with the positive revenue news, investors on the ASX were drove down the price of ResMed shares by 2.5% in early trading, although they bounced back at midday to around $3.18, down 1.85% on Thursday's close.
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
Self-destructing vaccine protects against TB in monkeys
A self-destructing vaccine administered intravenously provides additional safety and protection...
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
